Low-grade astrocytoma

Summary

Low-grade astrocytoma (MONDO:0016685) is a disease (an umbrella term covering 5 Mondo subtypes) and 4 clinical trials. Top therapeutic interventions include selumetinib, carboplatin, and vinblastine sulfate. A subtype of astrocytoma (excluding glioblastoma) — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 5 Mondo subtypes
• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	low-grade astrocytoma
Mondo ID	MONDO:0016685
Orphanet	251592
UMLS	C1314694
MedGen	727259
GARD	0020706
MedDRA	10065869
Is cancer (heuristic)	no

Disease family

This is a subtype of astrocytoma (excluding glioblastoma). Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › nervous system neoplasm › neuroepithelial neoplasm › glioma › astrocytic tumor › astrocytoma (excluding glioblastoma) › low-grade astrocytoma

Related subtypes (4): cauda equina intradural extramedullary astrocytoma, spinal cord astrocytoma, anaplastic astrocytoma, brain astrocytoma

Subtypes (5): pituicytoma, diffuse astrocytoma, pleomorphic xanthoastrocytoma, pilocytic astrocytoma, subependymal giant cell astrocytoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	2
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04166409	PHASE3	RECRUITING	A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
NCT04576117	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma
NCT00003468	PHASE2	COMPLETED	Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma
NCT06930846	Not specified	RECRUITING	HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SELUMETINIB	4	4
CARBOPLATIN	4	1
VINBLASTINE SULFATE	4	1
CHEMBL376464	0	1